Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Quintyne, Keith Ian ^a   Baker, Shirley ^a   Wallis, Fintan ^a   Gupta, Rajnish ^a,b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; GLUTAMIC ACID; INTERFERON; IPILIMUMAB; METHADONE; OXYGEN; VALINE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; ANAMNESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INTERMITTENT THERAPY; DYSPNEA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG METASTASIS; MALE; MELANOMA; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; THORACOTOMY; TREATMENT RESPONSE;

EID: 84864663706     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.11.2011.5202     Document Type: Article

References (19)

1. Dummer R, Hauschild A, Guggenheim M, et al . Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up . Annals of Oncology 2010;21(Suppl 5):v194-7.
2. Julia F, Thomas L, Dumontet C, et al . Targeted therapies in metastatic melanoma: toward a clinical breakthrough? Anticancer Agents Med Chem 2010;10:661-5.
3. Tsai J, Lee JT, Wang W, e t al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105:3041-6.
4. Jakob JA, B assett RL, Ng CS, e t al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma . J Clin Oncol 2011;29(Suppl; abstr 8500).
5. Elder DE. Thin melanoma . Arch Pathol Lab Med 2001;135:342-6.
6. Gimotty PA, Guerry D . Prognostication in thin cutaneous melanomas. Arch Pathol Lab Med 2010;134:1758-63.
7. Burton AL, Gilbert J, Farmer RW, e t al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg 2011;77:1009-13.
8. Egger ME, Gilbert JE, Burton AL, e t al. Lymphovascular invasion as a prognostic factor in melanoma. Am Surg 2011;77:992-7.
9. Lin K, Baritaki S, Militello L, et al . The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-κB/Snail/ RKIP/PTEN Circuit. Genes Cancer 2010;1:409-20.
10. Russo AE, Torrisi E, Bevelacqua Y, e t al . Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009;34:1481-9.
11. Miller AJ, Mihm MC JrMelanoma. N Engl J Med 2006;355:51-65.
12. El-Osta H, Falchook G, Tsimberidou A, e t al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS ONE 2011;6:e25806.
13. Chapman PB, Hauschild A, Robert C, e t al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
14. Poulikakos PI, Persaud Y, Janakiraman M, et al . RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
15. Kefford R, Arkenau H, Brown MP, e t al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumours . J Clin Oncol 2010;28(Suppl; abstr 8503):15s.
16. http://www.nccn.org/clinical-trials/investigators/rfp/pdf/braf.pdf (accessed 21 January 2012).
17. Arkenau HT, Kefford R, Long GV . Targeting BRAF for patients with melanoma. Br J Cancer 2011;104:392-8.
18. Chapman PB, Hauschild A, Robert C, e t al. Phase III randomized, openlabel, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma . J Clin Oncol 2011;29(Suppl; abstr LBA4).
19. http://www.cancer.gov/ncicancerbulletin/061411/page2 (accessed 12 September 2011).